| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 10 Aug 2026 | 10 Aug 2026 |
| Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on August 10, 2026. | ||
| Board Meeting | 30 Jul 2026 | 16 Jul 2026 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended on June 30 2026 To consider and approve the financial results for the period ended Jun 30, 2026 As Per NSE Announcement Dated On : 16.07.2026) | ||
| Board Meeting | 11 Jul 2026 | 11 May 2026 |
| Please find attached Outcome of Board Meeting held on July 11, 2026 | ||
| Board Meeting | 19 May 2026 | 7 May 2026 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 inter alia to consider and approve standalone and consolidated audited financial results of the Company for the quarter and financial year ended on March 31 2026 and realignment of security cover provided in respect of existing Non-Convertible Debentures. Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026. (As Per NSE Announcement Dated on : 19.05.2026) | ||
| Board Meeting | 13 Apr 2026 | 13 Apr 2026 |
| Mankind Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on April 13, 2026. | ||
| Board Meeting | 3 Feb 2026 | 9 Jan 2026 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 inter alia to consider and approve approval of unaudited standalone and consolidated financial results of the company for the quarter and nine months ended on December 31 2025. Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. (As Per NSE Announcement Dated On : 03.02.2026) | ||
| Board Meeting | 6 Nov 2025 | 27 Oct 2025 |
| Mankind Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30 2025. Un-audited Financial Results for the Quarter and Half Year ended 30.09.2025 Financial Results for the quarter and half year ended 30th September 2025 (As Per BSE Announcement Dated on: 06/11/2025) | ||
The company also informed that its diluted earnings per share (EPS) slipped by 20.10% on a yearly basis to ₹10.60.
Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.
The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.
Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.
The cumulative demand, including interest charges, is ₹183.11 crore.
The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.
The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.
Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.
The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.
The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
